Lipid nanoparticles (LNPs) have revolutionized the field of drug delivery through their
applications in siRNA delivery to the liver (Onpattro) and their use in the Pfizer-BioNTech …

Alzheimer's disease (AD) is the most common form of dementia. AD brain pathology starts
decades before the onset of clinical symptoms. One early pathological hallmark is blood …

Alzheimer's disease is a neurodegenerative disorder that causes age-dependent
neurological and cognitive declines. The treatments for Alzheimer's disease pose a …

Alzheimer's disease (AD) is the leading cause of dementia worldwide. Most AD patients
develop the disease in late life, named late onset AD (LOAD). Currently, the most …

Alzheimer's disease (AD) is a frequent and disabling neurodegenerative disorder, in which
astrocytes participate in several pathophysiological processes including neuroinflammation …

The blood-brain barrier (BBB) is a selective barrier and a functional gatekeeper for the
central nervous system (CNS), essential for maintaining brain homeostasis. The BBB is …

Complement is involved in developmental synaptic pruning and pathological synapse loss
in Alzheimer's disease. It is posited that C1 binding initiates complement activation on …

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a
complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging …

Alzheimer's disease (AD) has been the most extensively studied neurological disorders that
affects millions of individuals globally and is associated with misfolding of proteins in the …

The accumulation of abnormal aggregation of amyloid-β plaques is one of the most
distinguishing pathologies of Alzheimer's disease (AD) and is highly toxic to neurons …